Factor Bioscience tied to Tempest (NASDAQ: TPST) CEO buys 231,482 shares

Rhea-AI Filing Summary

Tempest Therapeutics director and CEO Matthew Angel reported an indirect open-market purchase of 231,482 shares of Common Stock at $2.16 per share. The shares are held by Factor Bioscience Inc., where he serves as chief executive officer and chairman, and he disclaims beneficial ownership except for his proportionate pecuniary interest.

Following this transaction, Factor Bioscience Inc. holds 231,482 shares indirectly attributed to Angel, while he also directly holds 4,837,070 shares of Tempest Therapeutics Common Stock. A footnote explains that the reported holdings reflect pro rata share distributions by Erigen LLC that changed only the form of his ownership.

Insider Trade Summary

Net Buyer: 231,482 shares ($500,001)

Net Buy 2 txns

Insider Angel Matthew

Role CEO and President

Bought 231,482 shs ($500K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	231,482	$2.16	$500K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 231,482 shares (Indirect, By Factor Bioscience Inc.); Common Stock — 4,837,070 shares (Direct)

Footnotes (1)

1. The shares are held by Factor Bioscience Inc. ("Factor"). The Reporting Peron is the chief executive officer and chairman of the board of directors of Factor and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein. The shares reported herein give effect to the pro rata distributions of shares by Erigen LLC for no additional consideration to its members, subsequent to the Reporting Person's last Section 16 filing reporting ownership of the Issuer's Common Stock. As the distribution of such shares constituted only a change in the form the Reporting Person's ownership in such shares, the Reporting Person was not required to report the distribution pursuant to Section 16.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Angel Matthew

(Last) (First) (Middle)

C/O TEMPEST THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 400

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tempest Therapeutics, Inc. [ TPST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/24/2026		P		231,482	A	$2.16	231,482	I	By Factor Bioscience Inc.(1)
Common Stock								4,837,070(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares are held by Factor Bioscience Inc. ("Factor"). The Reporting Peron is the chief executive officer and chairman of the board of directors of Factor and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

2. The shares reported herein give effect to the pro rata distributions of shares by Erigen LLC for no additional consideration to its members, subsequent to the Reporting Person's last Section 16 filing reporting ownership of the Issuer's Common Stock. As the distribution of such shares constituted only a change in the form the Reporting Person's ownership in such shares, the Reporting Person was not required to report the distribution pursuant to Section 16.

	/s/ Matthew Angel	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Tempest Therapeutics (TPST) report for Matthew Angel?

Tempest Therapeutics reported that Matthew Angel had an indirect open-market purchase of 231,482 shares of Common Stock at $2.16 per share. The shares are held by Factor Bioscience Inc., and Angel reports them due to his executive roles there and pecuniary interest.

Who actually holds the newly purchased TPST shares linked to Matthew Angel?

The newly purchased 231,482 Tempest Therapeutics shares are held by Factor Bioscience Inc. Matthew Angel is Factor’s chief executive officer and board chairman, and he disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest in the entity.

How many Tempest Therapeutics shares does Matthew Angel hold directly after this Form 4?

After the reported transactions, Matthew Angel directly holds 4,837,070 shares of Tempest Therapeutics Common Stock. This direct position is separate from the 231,482 shares held indirectly through Factor Bioscience Inc., which are reported with a beneficial ownership disclaimer.

What price did Factor Bioscience pay for the TPST shares reported on this Form 4?

Factor Bioscience Inc. acquired 231,482 Tempest Therapeutics Common Stock shares at $2.16 per share in an open-market purchase. This transaction is reported as an indirect holding for Matthew Angel because of his executive roles and financial interest in Factor Bioscience Inc.

What does the Form 4 say about Erigen LLC’s role in Matthew Angel’s TPST holdings?

The filing notes that the reported holdings give effect to pro rata share distributions by Erigen LLC to its members for no additional consideration. This distribution only changed the form of Matthew Angel’s ownership, so it was not separately reportable under Section 16 rules.

Does Matthew Angel fully own the TPST shares held by Factor Bioscience Inc.?

The Form 4 states that Matthew Angel disclaims beneficial ownership of the Tempest Therapeutics shares held by Factor Bioscience Inc., except to the extent of his proportionate pecuniary interest. This means he reports them due to economic interest rather than full direct ownership or sole control.